pING-HER3 Vaccine for Cancer

pING-HER3 Vaccine for Cancer

Es posible que algunos contenidos no estén disponibles en español.

Purpose of this Study

We are doing this study to find out how an experimental vaccine (pING-hHER3FL) works in your body and against your cancer.

Who Can Participate?

Eligibility

People who have gotten previous treatment with surgery and/or chemotherapy + radiation for one of the following cancers:
  • Breast
  • Colon
  • Lung
  • Prostate
  • Ovarian
  • Cervical
  • Endometrial
  • Gastric (stomach)
  • Pancreatic
  • Bladder
  • Head and neck
  • Liver
  • Esophageal
For more information about who can join this study, please contact the study team at felecia.walton@duke.edu.

What is Involved?

Description

If you choose to join this study, you will:
  • Get the study vaccine three times over 8 weeks
  • Have occasional blood draws for 5 years
  • Have a biopsy to collect tumor tissue, if necessary

Study Details

Full Title

ASSESSING THE IMMUNOGENICITY OF pING-hHER3FL VACCINE IN PATIENTS WITH RESECTED MALIGNANCIES

Principal Investigator

Michael
Morse

Protocol Number

PRO00104093

NCT ID

NCT03832855

Phase

I

Enrollment Status

Open to Enrollment
ClinicalTrials.gov